| I-08 Bambang Adiwijaya Component score models of HAMD were more predictive than total score models Wednesday 09:50-11:15 |
| I-19 Muhammad Waqar Ashraf Mechanistic model to characterize the pharmacokinetics and -dynamics of subcutaneous dexmedetomidine in healthy adult volunteers Wednesday 09:50-11:15 |
| I-45 Irina Bondareva Population pharmacokinetics of levetiracetam (LEV) in preterm neonates with seizures based on sparse therapeutic drug monitoring (TDM) data Wednesday 09:50-11:15 |
| I-48 Agnieszka Borsuk-De Moor The influence of age and body weight on pharmacokinetics and pharmacodynamics of dexmedetomidine in rabbits Wednesday 09:50-11:15 |
| I-61 Fernando Carreño Population Pharmacokinetic Modeling of Quetiapine Lipid Core Nanocapsules in a Neurodevelopmental Animal Model of Schizophrenia Wednesday 09:50-11:15 |
| I-65 Anne Chain A Model Based Meta-Analysis of second generation antipsychotics for the treatment of Schizophrenia Wednesday 09:50-11:15 |
| I-81 Kim Dao Pharmacokinetic Profile of Sultiame in Healthy Volunteers with In Vitro Characterization of Its Uptake by Red Blood Cells Wednesday 09:50-11:15 |
| II-38 Nicolás Marco Ariño Pharmacodynamic modelling of pupil diameter after noxious stimulus in patients undergoing surgery Wednesday 15:10-16:40 |
| II-42 Mark Meerson Quantitative systems pharmacology model of key intraneuronal pathways regulating toxic protein accumulation in Alzheimer’s disease Wednesday 15:10-16:40 |
| II-50 Jonathan Mochel A Physiologically-Based Pharmacokinetic (PBPK) Model for the Prediction of Levodopa (L-dopa) Disposition in Plasma and Various Brain Compartments Across Species Wednesday 15:10-16:40 |
| II-64 Andrés Olivares-Morales Bayesian pharmacokinetic (PK) and pharmacodynamic (PD) modelling of the qEEG response to a selective GABAA a5 receptor modulator in rats to inform its use as a translational biomarker Wednesday 15:10-16:40 |
| III-12 Marina Savelieva Modeling decline in cognition to decline in function in Alzheimer’s disease Thursday 09:55-11:20 |
| III-89 Xuan Zhou Model-Based Estimation of Probability of Pharmacological Success for CNS Compounds Thursday 09:55-11:20 |
| IV-48 Thomas Henthorn A population pharmacokinetic model of dense delta-9-tetrahydrocannabinol (THC), 11-OH-THC, and THCCOOH data and its use to estimate daily exposure in an observational cannabis study with sparse data Thursday 15:25-16:50 |
| IV-55 Ziad Hussein Population Pharmacokinetics of Lemborexant, a Dual Orexin Receptor Antagonist, in Healthy Adult and Elderly Subjects and Subjects with Primary Insomnia Thursday 15:25-16:50 |
| IV-74 Tatiana Karelina Amyloid β in vitro prion properties and in vivo pathology exacerbation mechanisms studied by translation quantitative systems pharmacology model for prediction of anti-protofibril immunotherapy effects Thursday 15:25-16:50 |
| IV-83 Seoyoung Kim Population Pharmacokinetic-Pharmacodynamic Modeling of Escitalopram in Patients with Obsessive-Compulsive Disorder Using Yale-Brown Obsessive Compulsive Scale Thursday 15:25-16:50 |
